Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cerebrospinal fluid (CSF) has been associated with Alzheimer's disease (AD). TREM2 plays a critical role in microglial activation, survival, and phagocytosis; however, the pathophysiological role of sTREM2 in AD is not well understood. Understanding the role of sTREM2 in AD may reveal new pathological mechanisms and lead to the identification of therapeutic targets. We performed a genome-wide association study (GWAS) to identify genetic modifiers of CSF sTREM2 obtained from the Alzheimer's Disease Neuroimaging Initiative. Common variants in the membrane-spanning 4-domains subfamily A (MS4A) gene region were associated with CSF sTREM2 concentrations (rs1582763; P = 1.15 × 10-15); this was replicated in independent datasets. The variants associated with increased CSF sTREM2 concentrations were associated with reduced AD risk and delayed age at onset of disease. The single-nucleotide polymorphism rs1582763 modified expression of the MS4A4A and MS4A6A genes in multiple tissues, suggesting that one or both of these genes are important for modulating sTREM2 production. Using human macrophages as a proxy for microglia, we found that MS4A4A and TREM2 colocalized on lipid rafts at the plasma membrane, that sTREM2 increased with MS4A4A overexpression, and that silencing of MS4A4A reduced sTREM2 production. These genetic, molecular, and cellular findings suggest that MS4A4A modulates sTREM2. These findings also provide a mechanistic explanation for the original GWAS signal in the MS4A locus for AD risk and indicate that TREM2 may be involved in AD pathogenesis not only in TREM2 risk-variant carriers but also in those with sporadic disease.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Conflict of interest statement
Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels.Neurobiol Aging. 2019 Dec;84:241.e13-241.e20. doi: 10.1016/j.neurobiolaging.2019.05.008. Epub 2019 May 21. Neurobiol Aging. 2019. PMID: 31204042
Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer's Disease.Front Aging Neurosci. 2019 Oct 25;11:297. doi: 10.3389/fnagi.2019.00297. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31708768 Free PMC article.
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.Acta Neuropathol. 2016 Jun;131(6):925-33. doi: 10.1007/s00401-016-1533-5. Epub 2016 Jan 11. Acta Neuropathol. 2016. PMID: 26754641 Free PMC article.
TREMs in Alzheimer's disease: Genetic and clinical investigations.Clin Chim Acta. 2016 Dec 1;463:88-95. doi: 10.1016/j.cca.2016.10.022. Epub 2016 Oct 18. Clin Chim Acta. 2016. PMID: 27769848 Review.
TREM2-Dependent Effects on Microglia in Alzheimer's Disease.Front Aging Neurosci. 2018 Jul 9;10:202. doi: 10.3389/fnagi.2018.00202. eCollection 2018. Front Aging Neurosci. 2018. PMID: 30038567 Free PMC article. Review.
Cited by 7 articles
TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease.Front Immunol. 2020 Apr 23;11:724. doi: 10.3389/fimmu.2020.00724. eCollection 2020. Front Immunol. 2020. PMID: 32391019 Free PMC article. Review.
The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer's Disease.Front Aging Neurosci. 2019 Nov 26;11:328. doi: 10.3389/fnagi.2019.00328. eCollection 2019. Front Aging Neurosci. 2019. PMID: 32038221 Free PMC article.
Friend, Foe or Both? Immune Activity in Alzheimer's Disease.Front Aging Neurosci. 2019 Dec 10;11:337. doi: 10.3389/fnagi.2019.00337. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31920620 Free PMC article. Review.
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease.Ther Adv Neurol Disord. 2019 Dec 18;12:1756286419888819. doi: 10.1177/1756286419888819. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 31897088 Free PMC article. Review.
Lipid rafts in glial cells: role in neuroinflammation and pain processing.J Lipid Res. 2020 May;61(5):655-666. doi: 10.1194/jlr.TR119000468. Epub 2019 Dec 20. J Lipid Res. 2020. PMID: 31862695 Review.
- P50 AG016574/AG/NIA NIH HHS/United States
- R01 AG057777/AG/NIA NIH HHS/United States
- R01 AG018023/AG/NIA NIH HHS/United States
- RF1 AG053303/AG/NIA NIH HHS/United States
- P01 AG026276/AG/NIA NIH HHS/United States
- P01 AG003991/AG/NIA NIH HHS/United States
- R01 NS080820/NS/NINDS NIH HHS/United States
- T32 AG000213/AG/NIA NIH HHS/United States
- RF1 AG044546/AG/NIA NIH HHS/United States
- U24 NS072026/NS/NINDS NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- U01 AG006786/AG/NIA NIH HHS/United States
- U19 AG032438/AG/NIA NIH HHS/United States
- U01 AG058922/AG/NIA NIH HHS/United States
- R01 AG032990/AG/NIA NIH HHS/United States
- R01 AG044546/AG/NIA NIH HHS/United States
- U01 AG046139/AG/NIA NIH HHS/United States
- K01 AG046374/AG/NIA NIH HHS/United States
- P01 AG017216/AG/NIA NIH HHS/United States
- RF1 AG058501/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- R01 HL119813/HL/NHLBI NIH HHS/United States